From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs)

Steroids

Volumn 90, Issue , 2014, Pages 30-38

  Wardell, Suzanne E ^a   Nelson, Erik R ^a   McDonnell, Donald P ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Estrogen receptor; Selective estrogen receptor modulator; SERM; Tamoxifen; TSEC

Indexed keywords

27-HYDROXYCHOLESTEROL; CHOLESTEROL DERIVATIVE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ANIMAL; CARDIOVASCULAR SYSTEM; DRUG EFFECTS; HUMAN; MAMMARY GLAND; METABOLISM;

ANIMALS; CARDIOVASCULAR SYSTEM; ESTROGEN RECEPTOR ALPHA; HUMANS; HYDROXYCHOLESTEROLS; MAMMARY GLANDS, HUMAN; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84908668490     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2014.07.013     Document Type: Article

References (104)

1. J.E. Rossouw, G.L. Anderson, R. Prentice, A.Z. LaCroix, C. Kooperberg, and M.L. Stefanick Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
2. V.C. Jordan, E. Phelps, and J.U. Lindgren Effects of anti-estrogens in castrated and intact female rats Breast Cancer Res Treat 10 1987 31 35
3. M.M. Gottardis, S.P. Robinson, P.G. Satyaswaroop, and V.C. Jordan Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse Cancer Res 48 1988 812 815
4. E. Ferrazzi, G. Cartei, R. Mattarazzo, and M. Fiorentino Oestrogen-like effect of tamoxifen on vaginal epithelium Br Med J 1 1977 1351 1352
5. L.J. Black, and R.L. Goode Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice Life Sci 26 1980 1453 1458
6. R.N. Kurl, and N.M. Borthwick Clomiphene and tamoxifen action in the rat uterus J Endocr 85 1980 519 524
7. A. Gotfredsen, C. Christiansen, and T. Palshof The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer Cancer 53 1984 853 857
8. S. Turken, E. Siris, D. Seldin, E. Flaster, G. Hyman, and R. Lindsay Effects of tamoxifen on spinal bone density in women with breast cancer J Natl Cancer Inst 81 1989 1086 1088
9. R.R. Love, R.B. Mazess, H.S. Barden, S. Epstein, P.A. Newcomb, and V.C. Jordan Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer New Engl J Med 326 1992 852 856
10. L.J. Black, M. Sato, E.R. Rowley, D.E. Magee, A. Bekele, and D.C. Williams Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats J Clin Invest 93 1994 63 69
11. A.U. Buzdar, C. Marcus, F. Holmes, V. Hug, and G. Hortobagyi Phase II evaluation of LY156758 in metastatic breast cancer Oncology 45 1988 344 345
12. B. Ettinger, D.M. Black, B.H. Mitlak, R.K. Knickerbocker, T. Nickelsen, and H.K. Genant Reduction of vertebral risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 1999 637 645
13. V.G. Vogel, J.P. Costantino, D.L. Wickerham, W.M. Cronin, R.S. Cecchini, and J.N. Atkins Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer Cancer Prev Res (Phila Pa) 3 2010 696 706
14. C.P. Miller SERMs: evolutionary chemistry, revolutionary biology Curr Pharm Des 8 2002 2089 2111
15. C.P. Miller, M.D. Collini, B.D. Tran, H.A. Harris, Y.P. Kharode, and J.T. Marzolf Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens J Med Chem 44 2001 1654 1657
16. D.P. McDonnell, D.L. Clemm, T. Hermann, M.E. Goldman, and J.W. Pike Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens Mol Endocrinol 9 1995 659 668
17. M.J.K. Harper, and A.L. Walpole Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes Nature 212 1966 87 89
18. C.H. Turner, M. Sato, and H.U. Bryant Raloxifene preserves bone strength and bone mass in ovariectomized rats Endocrinology 135 1994 2001 2005
19. R.T. Turner, G.K. Wakley, K.S. Hannon, and N.H. Bell Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats J Bone Miner Res 2 1987 449 456
20. M.M. Gottardis, and V.C. Jordan Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration Cancer Res 48 1988 5183 5187
21. D.P. McDonnell, E. Vegeto, and B.W. O'Malley Identification of a negative regulatory function for steroid receptors Proc Natl Acad Sci USA 89 1992 10563 10567
22. S.A. Onate, S. Tsai, M.-J. Tsai, and B.W. O'Malley Sequence and characterization of a coactivator for the steroid hormone receptor superfamily Science 270 1995 1354 1357
23. C.L. Smith, Z. Nawaz, and B.W. O'Malley Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen Mol Endocrinol 11 1997 657 666
24. A.L. Wijayaratne, S.C. Nagel, L.A. Paige, D.J. Christensen, J.D. Norris, and D.M. Fowlkes Comparative analyses of the mechanistic differences among antiestrogens Endocrinology 140 1999 5828 5840
25. S.L. Anzick, J. Kononen, R.L. Walker, D.O. Azorsa, M.M. Tanner, and X.-Y. Guan AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer Science 277 1997 965 968
26. C.K. Osborne, V. Bardou, T.A. Hopp, G.C. Chamness, S.G. Hilsenbeck, and S.A.W. Fuqua Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer J Natl Cancer Inst 95 2003 353 361
27. A.M. Redmond, F.T. Bane, A.T. Stafford, M. McIlroy, M.F. Dillon, and T.B. Crotty Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment: SRC-1 is an independent predictor of breast cancer recurrence Clin Cancer Res 15 2009 2098 2106
28. A.U. Buzdar, C. Marcus, F. Holmes, V. Hug, and G. Hortobachi Phase II evaluation of LY156758 in metastatic breast cancer Oncology 45 1988 144 145
29. J.D. Norris, L.A. Paige, D.J. Christensen, C.-Y. Chang, M.R. Huacani, and D. Fan Peptide antagonists of the human estrogen receptor Science 285 1999 744 746
30. A.M. Brzozowski, A.C. Pike, Z. Dauter, R.E. Hubbard, T. Bonn, and O. Engstrom Molecular basis of agonism and antagonism in the oestrogen receptor Nature 389 1997 753 758
31. A.K. Shiau, D. Barstad, P.M. Loria, L. Cheng, P.J. Kushner, and D.A. Agard The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen Cell 95 1998 927 937
32. V.G. Vogel The NSABP Study of Tamoxifen and Raloxifene (STAR) trial Expert Rev Anticancer Ther 9 2009 51 60
33. V.G. Vogel, J.P. Costantino, D.L. Wickerham, W.M. Cronin, R.S. Cecchini, and J.N. Atkins Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes JAMA 295 2007 2727 2741
34. C.-Y. Chang, J.D. Norris, H. Gron, L.A. Paige, P.T. Hamilton, and D.J. Kenan Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors α and β Mol Cell Biol 19 1999 8226 8239
35. J.D. Norris, L.A. Paige, D.J. Christensen, C.Y. Chang, M.R. Huacani, and D. Fan Peptide antagonists of the human estrogen receptor Science 285 1999 744 746
36. Y.-L. Wu, X. Yang, Z. Ren, D.P. McDonnell, J.D. Norris, and T.M. Willson Structural basis for an unexpected mode of SERM-mediated ER antagonism Mol Cell 18 2005 413 424
37. C.E. Connor, J.D. Norris, G. Broadwater, T.M. Willson, M.M. Gottardis, and M.W. Dewhirst Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor Cancer Res 61 2001 2917 2922
38. B. Wittmann, A. Sherk, and D. McDonnell Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators Cancer Res 67 2007 9549 9560
39. S. Chia, W. Gradishar, L. Mauriac, J. Bines, F. Amant, and M. Federico Double-blind, randomized placebo controlled trial of Fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT J Clin Oncol 26 2008 1664 1670
40. A. Di Leo, G. Jerusalem, L. Petruzelka, R. Torres, I. Bondarenko, and R. Khasanov Results of the CONFIRM Phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor positive advanced breast cancer J Clin Oncol 28 2010 4594 4600
41. A.D. Leo, G. Jerusalem, L. Petruzelka, R. Torres, I. Bondarenko, and R. Khasanov CONFIRM: a Phase III, randomized, parallel-group trial comparing fulvestrant 250 mg vs fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer Cancer Res 69 2009 [Abstract nr 25]
42. R.C. Dardes, R.M. O'Regan, C. Gajdos, S.P. Robinson, D. Bentrem, and A.D.L. Reyes Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo Clin Cancer Res 8 2002 1995 2001
43. T.M. Willson, J.D. Norris, B.L. Wagner, I. Asplin, P. Baer, and H.R. Brown Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of ER in bone Endocrinology 138 1997 3901 3911
44. I. Mayer, A. Bardia, M. Dickler, H. Manning, U. Mahmood, and G. Ulaner Abstract OT3-2-07: phase I study of ARN-810, a novel selective estrogen receptor degrader, in post-menopausal women with locally advanced or metastatic estrogen receptor positive breast cancer Cancer Res 73 2013 [Abstract nr OT3-2-07]
45. S.E. Wardell, E.R. Nelson, C.A. Chao, and D.P. McDonnell Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease Clin Cancer Res 19 2013 2420 2431
46. J. Lewis-Wambi, H. Kim, R. Curpan, R. Grigg, M. Sarker, and V. Jordan The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and downregulates estrogen receptor α and cyclin D1 Mol Pharmacol 80 4 2011 610 620
47. T.L. Ramsey, K.E. Risinger, S.C. Jernigan, K.A. Mattingly, and C.M. Klinge Estrogen receptor beta isoforms exhibit differences in ligand-activated transcriptional activity in an estrogen response element sequence-dependent manner Endocrinology 145 2004 149 160
48. T. Barkhem, B. Carlsson, Y. Nilsson, E. Enmark, J. Gustafsson, and S. Nilsson Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists Mol Pharmacol 54 1998 105 112
49. G.G.J.M. Kuiper, B. Carlsson, K. Grandien, E. Enmark, J. Häggblad, and S. Nilsson Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β Endocrinology 138 1997 863 870
50. J.M. Hall, and D.P. McDonnell The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens Endocrinology 140 1999 5566 5578
51. J.B. Bruning, A.A. Parent, G. Gil, M. Zhao, J. Nowak, and M.C. Pace Coupling of receptor conformation and ligand orientation determine graded activity Nat Chem Biol 6 2010 837 843
52. A.C. Gee, K.E. Carlson, P.G.V. Martini, B.S. Katzenellenbogen, and J.A. Katzenellenbogen Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor Mol Endocrinol 13 1999 1912 1923
53. V.S. Likhite, F. Stossi, K. Kim, B.S. Katzenellenbogen, and J.A. Katzenellenbogen Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity Mol Endocrinol 20 2006 3120 3132
54. J.C. Reese, and B.S. Katzenellenbogen Differential DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: studies using human estrogen receptor overexpressed in mammalian cells Nucleic Acids Res 19 1991 6595 6602
55. J.M. Hall, D.P. McDonnell, and K.S. Korach Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements Mol Endocrinol 16 2002 469 486
56. M.R. McClung, E. Siris, S. Cummings, M. Bolognese, M. Ettinger, and A. Moffett Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene Menopause 13 2006 377 386
57. A.Z. LaCroix, T. Powles, C.K. Osborne, K. Wolter, J.R. Thompson, and D.D. Thompson Breast cancer incidence in the randomized PEARL Trial of lasofoxifene in postmenopausal osteoporotic women J Natl Cancer Inst 102 22 2010 1706 1715
58. S.R. Cummings, K. Ensrud, P.D. Delmas, A.Z. LaCroix, S. Vukicevic, and D.M. Reid Lasofoxifene in postmenopausal women with osteoporosis N Engl J Med 362 2010 686 696
59. S.R. Goldstein, P. Neven, S. Cummings, T. Colgan, C.D. Runowicz, and D. Krpan Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial: 5-year gynecological outcomes Menopause 18 2011 17 22
60. P.D. Miller, A.A. Chines, C. Christiansen, H.C. Hoeck, D.L. Kendler, and E.M. Lewiecki Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study J Bone Miner Res 23 2008 525 535
61. S.L. Silverman, C. Christiansen, H.K. Genant, S. Vukicevic, J.R. Zanchetta, and T.J. de Villiers Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial J Bone Miner Res 23 2008 1923 1934
62. D.F. Archer, V. Lewis, B.R. Carr, S. Olivier, and J.H. Pickar Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women Fertil Steril 92 2009 1039 1044
63. C. Christiansen, C.H. Chesnut 3rd, J.D. Adachi, J.P. Brown, C.E. Fernandes, and A.W. Kung Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis BMC Musculoskelet Disord 11 2010 130
64. J.A. Harvey, M.K. Holm, R. Ranganath, P.A. Guse, E.A. Trott, and E. Helzner The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis Menopause 16 2009 1193 1196
65. M. Bolognese, J.H. Krege, W.H. Utian, R. Feldman, S. Broy, and D.L. Meats Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass J Clin Endocrinol Metab 94 2009 2284 2289
66. D.L. Kendler, S. Palacios, D.A. Cox, J. Stock, J. Alam, and S.A. Dowsett Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis Osteoporos Int 23 2012 1091 1101
67. T.J. Powles, S.J. Diem, C.J. Fabian, P. Neven, D.L. Wickerham, and D.A. Cox Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene Breast Cancer Res Treat 134 2012 299 306
68. D.S. McMeekin, A. Gordon, J. Fowler, A. Melemed, R. Buller, and T. Burke A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer Gynecol Oncol 90 2003 64 69
69. S.R. Goldstein, D.F. Archer, J.A. Simon, and G. Constantine Endometrial safety of ospemifene and the ability of transvaginal ultrasonography to detect small changes in endometrial thickness Obstet Gynecol 123 Suppl. 1 2014 96S 97S
70. S.K. Voipio, J. Komi, L. Kangas, K. Halonen, M.W. DeGregorio, and R.U. Erkkola Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women Maturitas 43 2002 207 214
71. D. Portman, S. Palacios, R.E. Nappi, and A.O. Mueck Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial Maturitas 78 2 2014 91 98
72. Q. Qu, H. Zheng, J. Dahllund, A. Laine, N. Cockcroft, and Z. Peng Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats Endocrinology 141 2000 809 820
73. J. Komi, K.S. Lankinen, M. DeGregorio, J. Heikkinen, S. Saarikoski, and M. Tuppurainen Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women J Bone Miner Metab 24 2006 314 318
74. J. Komi, J. Heikkinen, E.M. Rutanen, K. Halonen, R. Lammintausta, and O. Ylikorkala Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women Gynecol Endocrinol 18 2004 152 158
75. P.M. Sarrel, V.Y. Njike, V. Vinante, and D.L. Katz The mortality toll of estrogen avoidance. an analysis of excess deaths among hysterectomized women aged 50 to 59 years Am J Public Health 103 2013 1583 1588
76. G.L. Anderson, R.T. Chlebowski, A.K. Aragaki, L.H. Kuller, J.E. Manson, and M. Gass Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial Lancet Oncol 13 2012 476 486
77. G. Barbaglia, F. Macia, M. Comas, M. Sala, M. del Mar Vernet, and M. Casamitjana Trends in hormone therapy use before and after publication of the Women's Health Initiative trial: 10 years of follow-up Menopause 16 2009 1061 1064
78. J. Whiteley, J.S. Wagner, A. Bushmakin, L. Kopenhafer, M. Dibonaventura, and J. Racketa Impact of the severity of vasomotor symptoms on health status, resource use, and productivity Menopause 20 2013 518 524
79. K. Bakken, A. Fournier, E. Lund, M. Waaseth, V. Dumeaux, and F. Clavel-Chapelon Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition Int J Cancer 128 2011 144 156
80. V. Beral Million Women Study C Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 2003 419 427
81. S. Davis, S. O'Neill, J. Eden, R. Baber, A. Ekangaki, and J. Stocks Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium - a pilot study Menopause 11 2004 167 175
82. D.W. Stovall, W.H. Utian, M.L. Gass, Y. Qu, D. Muram, and M. Wong The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety Menopause 14 2007 510 517
83. J. Levine Treating menopausal symptoms with a tissue-selective estrogen complex Gender Med 8 2011 57 68
84. B.S. Komm, Y.P. Kharode, P.V. Bodine, H.A. Harris, C.P. Miller, and C.R. Lyttle Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity Endocrinology 146 2005 3999 4008
85. A. McTiernan, R.T. Chlebowski, C. Martin, J.D. Peck, A. Aragaki, and E.D. Pisano Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial J Clin Oncol 27 2009 6135 6143
86. J.A. Harvey, J.V. Pinkerton, E.C. Baracat, H. Shi, A.A. Chines, and S. Mirkin Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens Menopause 20 2013 138 145
87. J.V. Pinkerton, J.A. Harvey, R. Lindsay, K. Pan, A.A. Chines, and S. Mirkin Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial J Clin Endocrinol Metab 99 2014 E189 E198
88. H. Naqvi, S. Sakr, T. Presti, G. Krikun, B. Komm, and H.S. Taylor Treatment with bazedoxifene and conjugated estrogens results in regression of endometriosis in a murine model Biol Reprod 90 6 2014 121
89. M. Umetani, H. Domoto, A.K. Gormley, I.S. Yuhanna, C.L. Cummins, and N.B. Javitt 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen Nat Med 13 2007 1185 1192
90. S. Dzeletovic, O. Breuer, E. Lund, and U. Diczfalusy Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry Anal Biochem 225 1995 73 80
91. R. Karuna, A.G. Holleboom, M.M. Motazacker, J.A. Kuivenhoven, R. Frikke-Schmidt, and A. Tybjaerg-Hansen Plasma levels of 27-hydroxycholesterol in humans and mice with monogenic disturbances of high density lipoprotein metabolism Atherosclerosis 214 2011 448 455
92. C.D. DuSell, M. Umetani, P.W. Shaul, D.J. Mangelsdorf, and D.P. McDonnell 27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator Mol Endocrinol 22 2008 65 77
93. L. Brouchet, A. Krust, S. Dupont, P. Chambon, F. Bayard, and J.F. Arnal Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor alpha but not estrogen receptor beta Circulation 103 2001 423 428
94. C.D. DuSell, E.R. Nelson, X. Wang, J. Abdo, U.I. Modder, and M. Umetani The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis Endocrinology 151 2010 3675 3685
95. A. Tarakida, K. Iino, K. Abe, R. Taniguchi, T. Higuchi, and H. Mizunuma Hypercholesterolemia accelerates bone loss in postmenopausal women Climacteric 14 2011 105 111
96. T. Yamaguchi, T. Sugimoto, S. Yano, M. Yamauchi, H. Sowa, and Q. Chen Plasma lipids and osteoporosis in postmenopausal women Endocr J 49 2002 211 217
97. P. Orozco Atherogenic lipid profile and elevated lipoprotein (a) are associated with lower bone mineral density in early postmenopausal overweight women Eur J Epidemiol 19 2004 1105 1112
98. R. Karuna, A.V. Eckardstein, and K.M. Rentsch Dpant assisted-atmospheric pressure photoionization (DA-APPI) liquid chromatography-mass spectrometry for the quantification of 27-hydroxycholesterol in plasma J Chromatogr B 877 2009 261 268
99. D.C. Bauer, G.R. Mundy, S.A. Jamal, D.M. Black, J.A. Cauley, and K.E. Ensrud Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials Arch Intern Med 164 2004 146 152
100. G. Lupattelli, A.M. Scarponi, G. Vaudo, D. Siepi, A.R. Roscini, and F. Gemelli Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women Metabolism 53 2004 744 748
101. E.R. Nelson, S.E. Wardell, J.S. Jasper, S. Park, S. Suchindran, and M.K. Howe 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology Science 342 2013 1094 1098
102. Q. Wu, T. Ishikawa, R. Sirianni, H. Tang, J.G. McDonald, and I.S. Yuhanna 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth Cell Rep 5 2013 637 645
103. C.L. Smith, and B.W. O'Malley Coregulator function: a key to understanding tissue specificity of selective receptor modulators Endocr Rev 25 2004 45 71
104. V.C. Jordan, N.F. Fritz, and D.C. Tormey Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer Cancer Res 47 1987 624 630